Fidaxomicin

非达霉素

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameFidaxomicin
Drug Alias Namefidaxomicinum非达米星fidaxomicinafidaxomicineLipiarmycin +[12] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitors
TargetsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsDiarrheaEnteritisClostridium Infections
Global Approved IndicationsDiarrheaEnteritisClostridium Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/05/27
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaClinical
Originator CompaniesCubist Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesTillotts Pharma GmbhCubist Pharmaceuticals LlcAstellas Pharma Inc +[5] 
Inactive CompaniesUniversity Of AlbertaAstellas Pharma Europe BvMcmaster University +[6] 
Active IndicationsDiarrheaEnteritisClostridium Infections
Inactive IndicationsN/A

Other Information

ATC CodeA07AA12
Related LinksWikipediaDrugBankKEGG